Peter de Keizer

De Keizer has articulated a durable and reasonably specific therapeutic vision centered on selectively eliminating senescent cells and designing compounds that also stimulate tissue rejuvenation. This is an ambitious path toward reducing frailty and age-related disease, supported by a sustained FOXO4-p53 research and commercialization program. However, the evidence contains no explicit destination statement, human-lifespan target, development timeline, or comprehensive vision for ending aging or reversing systemic biological decline.

Strong scientific impact driven by a field-shaping senolytics paper with 1,456 citations, supported by nearly 3,000 total citations and several influential FOXO, senescence, and redox-signaling publications. The h-index of 18 is solid rather than exceptional, and impact is concentrated heavily in one landmark work, so the record falls short of broadly field-defining impact at the very highest tier.

Peter de Keizer is evidenced here as a scientist and founder, but the capital_deployed dimension evaluates outcomes from capital he personally allocated. The record contains no qualifying investments, donations, catalytic financing positions, or backed companies, so this dimension is inapplicable rather than merely unsuccessful.

No public capital deployment activity is evidenced: no investments or donations were found.

De Keizer shows a coherent progression from foundational FOXO and cellular-stress research to a highly influential targeted senescent-cell elimination strategy and biotechnology translation. This supports credible strategic taste in selecting a tractable, targeted intervention within aging biology. However, the evidence does not establish when Cleara was founded, how early or contrarian the bet was, whether his choices were counterfactually decisive, or whether the therapies achieved meaningful clinical validation.

De Keizer has a credible field-building achievement as founder and managing director of Cleara Biotech, an organization translating senescence research into targeted therapeutic development. This makes longevity work more actionable beyond academia, but the evidence does not establish the company's scale, durability, external influence, successful programs, or field-wide impact.

De Keizer showed moderate contrarian conviction by publicly advancing senescent-cell targeting and tissue rejuvenation when reversing aging was characterized as utopian. However, the evidence does not establish major personal downside, persistence through serious criticism, an unusually large bet relative to his capacity, or self-experimentation.

De Keizer has generated meaningful second-order leverage through a highly cited senescence study and the founding of Cleara Biotech, extending his research into a therapeutics organization. The evidence supports substantial scholarly follow-on activity, but does not establish broad talent attraction, capital mobilization, policy influence, or a wider founder ecosystem.